Navigation Links
PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial
Date:4/13/2011

es relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, at this point there can be no assurance that Valortim® will be shown to be safe and effective and approved by regulatory authorities for use in humans.  Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
8. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
9. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
10. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
11. PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 2011 Spherix Incorporated (NASDAQ: SPEX ) ... metabolic syndrome and atherosclerosis, and providers of technical and ... companies -- today announced that Dr. Claire Kruger, Chief ... presenting a corporate overview at the Rodman & Renshaw ...
... Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals ... Executive Officer, will present at the Rodman and Renshaw ... 2:25pm ET at the Waldorf Astoria Hotel in New ... Founded in 2008, Omthera Pharmaceuticals, Inc. ...
Cached Medicine Technology:Spherix Incorporated to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... SILVER SPRING, Md., Dec. 24 The American Nurses Association (ANA), ... for passing H.R. 3590, " The Patient Protection and Affordable ... vote of 60-39. ANA had urged passage of the legislation and ... members of Congress, was read on the Senate floor by Majority ...
... , , WASHINGTON, Dec. 24 ... Senate voted to pass the Patient Protection and Affordable Care ... bill on Christmas Eve, after overcoming a series of procedural ... stop the bill from ever reaching the Senate floor for ...
... Dec. 24 The American ... of legislation that holds the promise of more comprehensive coverage ... those without. , We are pleased that the ... our association,s principles for comprehensive health reform, and that the ...
... 24 The following statement is attributable to J. James ... Senate took an historic vote to improve our nation,s health ... strengthening the private insurance market to better serve the patients ... the bill because it contains a number of key improvements ...
... well-tolerated, researchers say , WEDNESDAY, Dec. 23 (HealthDay News) -- ... an effective treatment for Ewing,s sarcoma, a cancer that affects ... boys. , The drug must undergo two more phases of ... 23 online edition of The Lancet Oncology . , ...
... before proposal can become law , THURSDAY, Dec. 24 (HealthDay ... Eve gift on Thursday with passage of a landmark health ... Americans. , Obama said the Senate bill contains 95 percent ... inauguration on Jan. 20. "Every single criteria for reform that ...
Cached Medicine News:Health News:Senate Passes Landmark Health Care Reform Bill 2Health News:DNC Chairman Tim Kaine Calls Senate Vote Historic, Says Landmark Health Reform Bill Is a Victory for the American People 2Health News:APA Statement on Senate Passage of Health Care Reform Legislation 2Health News:AMA: Senate Bill Passage Historic, More Work to Do in Conference 2Health News:Senate Passes Health Reform Package 2Health News:Senate Passes Health Reform Package 3Health News:Senate Passes Health Reform Package 4
... SuperAnchors are titanium alloy implants ... to bone. They are indicated ... required. The SuperAnchor uses four ... while maintaining small size. The ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... protection' -- providing complete protection from initial ... with side branches. , ,Proxis is ... not require the attachment or exchange of ... ,Proxis is compatible with all standard ...
... electrophysiology system on the market today, the ... patented "C inside a C" design offering ... ultimate in patient access and flexibility. Usable ... minimizes equipment footprint and can be parked ...
Medicine Products: